FOXD3 and colon adenocarcinoma: Previous evidence has indicated that FOXD3-AS1 is upregulated in COAD tissues as well as in HCT116 and SW1116 cells, while its expression correlates with key clinical features, including: TNM stage, poor tumor differentiation, lymph node metastasis, overall survival and progression-free survival (36).